Targeting breast cancer stem cells

Breast

Volumn 18, Issue SUPPL.3, 2009, Pages

  Wicha, Max S ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

Metastasis; Self renewal; Stem cells

Indexed keywords

ALDEHYDE DEHYDROGENASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; NOTCH RECEPTOR;

ARTICLE; BREAST CANCER; CANCER MODEL; CANCER STEM CELL; CARCINOGENESIS; CELL DIFFERENTIATION; CELL LINEAGE; CELL RENEWAL; ENZYME ACTIVITY; HUMAN; IMMUNODETECTION; IMMUNOHISTOCHEMISTRY; METASTASIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TARGET CELL;

EID: 71749116906     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-9776(09)70274-7     Document Type: Article

References (19)

1. Dontu G., Abdallah W.M., Foley J.M., Jackson K.W., Clarke M.F., Kawamura M.J., et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 17 (2003) 1253-1270
2. Liu S., Dontu G., Mantle I.D., Patel S., Ahn N.S., Jackson K.W., et al. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res 66 (2006) 6063-6071
3. Kuperwasser C., Chavarria T., Wu M., Magrane G., Gray J.W., Carey L., et al. Reconstruction of functionally normal and malignant human breast tissues in mice. Proc Natl Acad Sci USA 101 (2004) 4966-4971
4. Armstrong L., Stojkovic M., Dimmick I., Ahmad S., Stojkovic P., Hole N., et al. Phenotypic characterization of murine primitive hematopoietic progenitor cells isolated on basis of aldehyde dehydrogenase activity. Stem Cells 22 (2004) 1142-1151
5. Ginestier C., Hur M., Charafe-Jauffret E., Monville F., Dutcher J., Brown M., et al. ALDH1 is a marker of normal and malignant breast stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1 (2007) 555-567
6. Dontu G., Jackson K.W., McNicholas E., Kawamura M.J., Abdallah W.M., and Wicha M.S. Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res 6 (2004) R605-R615
7. Korkaya H, Wicha M. Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. PLOS Biol 2009; in press.
8. Weaver V.M., and Bissell M.J. Functional culture models to study mechanisms governing apoptosis in normal and malignant mammary epithelial cells. J Mammary Gland Biol Neoplasia 4 (1999) 193-201
9. Bonnet D., and Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3 (1997) 730-737
10. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., and Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100 (2003) 3983-3988
11. Charafe-Jauffret E., Ginestier C., Iovino F., Wicinski J., Cervera N., Finetti P., et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 69 (2009) 1302-1313
12. Dontu G., El-Ashry D., and Wicha M.S. Breast cancer, stem/progenitor cells and the estrogen receptor. Trends Endocrinol Metab 15 (2004) 193-197
13. Balic M., Lin H., Young L., Hawes D., Giuliano A., McNamara G., et al. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res 12 (2006) 5615-5621
14. Yu F., Yao H., Zhu P., Zhang X., Pan Q., Gong C., et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 131 (2007) 1109-1123
15. Li X., Lewis M.T., Huang J., Gutierrez C., Osborne C.K., Wu M.F., et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100 (2008) 672-679
16. Korkaya H., Paulson A., Iovino F., and Wicha M.S. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 27 (2008) 6120-6130
17. Magnifico A., Albano L., Campaner S., Delia D., Castiglioni F., Gasparini P., et al. Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab. Clin Cancer Res 15 (2009) 2010-2021
18. Paik S., Kim C., and Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med 358 (2008) 1409-1411
19. Korkaya H., and Wicha M.S. HER-2, Notch, and breast cancer stem cells: targeting an Axis of Evil. Clin Cancer Res 15 (2009) 1845-1847